Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revis
Mirum Pharmaceuticals, Inc. (MIRM) shares soared 5.1% in the last trading session to close at $92.38. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.4% loss over the past four weeks.
Last month, Mirum completed enrollment in its phase III EXPAND study evaluating Livmarli (maralixibat) for cholestatic pruritus in patients aged six months and older with rare liver diseases, including biliary atresia. The study’s primary goal is to assess the reduction in itch severity by week 20, with additional biomarkers as secondary endpoints, and results are expected in the fourth quarter of 2026. The study could support a label expansion for Livmarli, an oral IBAT inhibitor already approved for Alagille syndrome and certain progressive familial intrahepatic cholestasis patients. This has likely been driving the stock price gain for the company.
This company is expected to post quarterly loss of $0.40 per share in its upcoming report, which represents a year-over-year change of -33.3%. Revenues are expected to be $149.1 million, up 33.6% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Mirum Pharmaceuticals, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on MIRM going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Mirum Pharmaceuticals belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Ocugen (OCGN), closed the last trading session 3.4% higher at $1.81. Over the past month, OCGN has returned -9.8%.
Ocugen's consensus EPS estimate for the upcoming report has changed +17.9% over the past month to -$0.05. Compared to the company's year-ago EPS, this represents no change. Ocugen currently boasts a Zacks Rank of #3 (Hold).
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Join 500,000+ readers who start their day with Quartz.
By subscribing, you agree to our Terms of Service and Privacy Policy.
